We assessed the mobilization capacity of taxol with rhG-CSF, both as a single chemotherapeutic agent and in the presence of cyclophosphamide (CY), and compared the effect with yields achieved when mobilization was performed solely with rhG-CSF. Fifteen patients with breast cancer received taxol 170 mg/m 2 (continuous infusion, day 1) and rhG-CSF (8 g/kg/day, from day 2 until the end of apheresis) (T-G group), while seven breast cancer patients were additionally treated with CY (4 g/m 2 ) on day 2, followed by rhG-CSF starting at similar doses on day 3 (T-CY-G group). The PBSC collections after taxol with/without CY were compared with those of 30 breast cancer patients who had received rhG-CSF (8 g/kg/day) for mobilization. 
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CD34
+ cells/kg, a threshold considered to be sufficient for hematopoietic reconstitution, were collected with a single apheresis. Those patients in the T-G group experienced less neutropenic and thrombocytopenic days, with all neutropenic fever episodes developing in patients treated with the T-CY-G schedule (43%). When considering priming with rhG-CSF alone in our historical cohort of 30 breast cancer patients, a significant detrimental effect was observed in comparison with taxol mobilizing schedules, in the number of aphereses performed, in the total yield CD34 + cells and in the number of patients who achieved the target dose of 2.5 × 10 The number of CD34 + cells infused in peripheral blood stem cell (PBSC) transplantation is related to hematological recovery, transfusion needs, and early outcomes of the procedure. Although recombinant hematopoietic growth factors, such as granulocyte colony-stimulating factor (rhG-CSF) are generally used in mobilization protocols, the optimal schedules for priming stem cells still remain to be established. It has been shown that the addition of chemotherapy to growth factors increases the yield of CD34 + cells, 1 but side-effects such as pancytopenia and infections, may limit the use of these drugs in some cases. In addition, cytotoxic agents might induce stromal damage in heavily pre-treated patients, negatively affecting the graft kinetics. Mobilizing chemotherapy regimens must be chosen from among those with proven activity against the underlying disease, and based on the oncological needs of the patient.
Taxol (Paclitaxel; Bristol-Myers Squibb, Princeton, NJ, USA) is a plant alkaloid that interferes with microtubule assembly. Taxol is effective against ovarian and breast cancers, and has also been proven active in lung cancer, leukemia, and lymphoma, among other human neoplasms. 2 The antitumor effect of taxol in breast cancer makes it especially useful for both pretransplant cytoreduction, and as a mobilizing agent in such patients. Previous data suggest that combination chemotherapy priming schedules containing taxol may increase the progenitor cell yields, and might also be beneficial against underlying neoplastic diseases, without causing apparent hematopoietic sideeffects. [3] [4] [5] [6] [7] [8] Thus, while taxol has been recently included in association with other chemotherapeutic agents, such as cyclophosphamide (CY) and doxorubicin, in mobilization regimens as being an integral part of therapy for the underlying disease, the drug as a single agent in association with rhG-CSF might theoretically be used specifically as a mobilization stimulant.
The aim of this in vivo prospective study was to assess the efficacy of taxol-rhG-CSF in the presence and absence of CY, for mobilizing PBPC. Moreover, we contrasted the priming of CD34
+ cells in such regimens, with that of rhG-
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CSF alone in a previously reported historical group of breast cancer patients.
Patients and methods
Patients
From July 1997 to March 1999, 22 women with breast cancer were treated with taxol containing schedules for PBSC mobilization. Inclusion criteria were chemotherapy-responsive disease, absence of bone marrow involvement, time elapsed from the last treatment of at least 4 weeks and recovery of peripheral blood counts to more than 1 × 10 9 /l neutrophils and 100 × 10 9 /l platelets. All patients gave informed consent.
Mobilization schemes
Fifteen patients received taxol 170 mg/m 2 by continuous infusion for 24 h (day 1) followed the next day by 8 g/kg rhG-CSF s.c. daily until the last apheresis (T-G group). Taxol was diluted in 500 ml of saline, in a glass container with polyethylene-lined tubing and a 0.22 m in-line filter. Premedication to prevent taxol-induced hypersensitivity consisted of dexamethasone 20 mg i.v., ranitidine 150 mg i.v., and dyphenhydramine 50 mg i.v., 30 min before taxol infusion.
Seven patients were treated with a protocol containing taxol as above, followed 24 h later by CY 4 g/m 2 as a 1-h infusion. On the third day, rhG-CSF was started s.c. at a dose of 8 g/kg each day until the completion of leukapheresis (T-CY-G group). Hyperhydration and Mesna were used to prevent hemorrhagic cystitis in patients included within this group. Prophylaxis with ciprofloxacin 500 mg orally twice a day was instituted during neutropenia (ANC Ͻ 0.5 × 10 9 /l). A historical cohort of 30 breast cancer patients mobilized with rhG-CSF alone at a dose of 8 g/kg/day, in whom collection procedures were initiated after three doses of the growth factor, was used in the analysis of the priming of CD34 + cells. Patient characteristics and mobilization data have been previously reported. 9 
Progenitor cell mobilization monitoring
Peripheral blood CD34
+ cell concentrations were assessed on the day before initiation of mobilization, daily after the second day of rhG-CSF treatment and in each apheresis product. A panel of three monoclonal antibodies (MoAb) was used for the analysis, as described elsewhere. 10 Briefly, aliquots of peripheral blood or apheresis products were incubated with FITC-conjugated CD14 (anti-LeuM3), PEconjugated CD34 (anti-HPCA-2), PerCP-conjugated CD45, and with irrelevant isotype controls (all MoAbs were from Becton Dickinson (BD), San Jose, CA, USA). Erythrocytes were then lysed with FACS lysing solution (BD) and after washing with PBS cells were acquired with a FACScalibur flow cytometer (BD) equipped with a 488 nm laser beam. The analysis was performed using the Paint-A-Gate Pro software. CD34
+ /CD14 + events and cells showing inadequate FSC/SSC characteristics were excluded, and the percentage of non-specific events was substracted from positive events in stained samples.
Apheresis procedure
Leukapheresis procedures were performed in the T-CY-G group either when the total white blood cell count exceeded 5 × 10 9 /l, or when peripheral blood CD34 + cells were Ͼ30/l whichever came first; the second premise was used to begin collection procedures in the T-G mobilized patients. Daily leukaphereses were executed until a target number of 2.5 × 10 6 CD34 + /kg recipient body weight was achieved, except in five patients (two in T-CY-G schedule and three in T-G) included in a double transplantation program, in whom a target dose of 5 × 10 6 CD34 + /kg recipient body weight was required, to allow the accomplishment of both procedures. Ten to 15 liters of blood were processed in each leukapheresis, using continuous flow centrifugation through central venous catheters (Hickman). Collections were performed using either COBE Spectra (six and four, in T-G and T-CY-G groups, respectively) (COBE BCT, Lakewood, CO, USA) or a Fenwall CS 3000 plus (nine in T-G and three in T-CY-G group) (Baxter, Fenwall Division, Round Lake, IL, USA) blood cell separators.
Statistics
An analysis to evaluate the influence of the priming treatments in the mobilization was performed using the MannWhitney U test with the SPSS 6.0 Statistical Package for Windows. Results are given as median values. A significance level of P Ͻ 0.05 was chosen.
Results
Patient characteristics
Twenty-two breast cancer patients were enrolled for mobilization using taxol containing schedules (15 T-G group, seven T-CY-G). Patient characteristics are shown in Table 1 . The median age was 43 years (range 33-62). They had received a median of one chemotherapy regimen (range 1-3), consisting of six chemotherapy cycles (range 4-13) prior to the mobilization treatment. Three had received previous radiotherapy. The disease status at diagnosis was as follows: three patients stage IIa; four IIb; six IIIa; two IIIb and seven with metastatic disease. At the time of mobilization 18 patients had no evidence of disease and four had a partial remission.
No differences in patient characteristics between T-G and T-CY-G groups were found except in age (median age of T-CY-G patients 51 years (range, 39-62), and in the T-G group of 38 years (range, 33-62), P = 0.002) ( Table 1) . Before commencement of mobilization, the concentration of leukocytes, neutrophils, lymphocytes, monocytes, platelets, hemoglobin, hematocrit values, and the peripheral blood steady state CD34 + cell counts, did not significantly differ between the groups (data not shown). Analysis of characteristics of subjects included in taxol bearing sched- ules and in the rhG-CSF mobilized historical group, revealed no statistical differences.
PBSC collections
PBSC leukaphereses were initiated in taxol containing schedules a median of 9 days (range 7 to 17), following the administration of taxane. The median number of peripheral blood CD34 + cells on the day when the first leukapheresis was performed was 60/l (range 1 to 320 cells/l), resulting in a median yield of 8 × 10 6 /kg CD34 + cells collected in the first procedure (range 0.03 to 25 × 10 6 /kg). Twenty out of 22 patients (90%) achieved the minimum threshold number of 2.5 CD34 + cells/kg within the first apheresis, and in 77.2% patients more than 5 × 10 6 /kg CD34 + cells were collected ( Table 2 ). The median number of procedures performed was one with a range of 1 to 4. The total yield of CD34 + cells was 9 × 10 6 /kg, with a range of 2 to 26 × 10 6 /kg. No patient included in either taxol priming schedule failed to mobilize PBSC, and only one individual did not achieve the minimum threshold number of 2.5 × 10 6 /kg CD34 + cells. The analysis of both taxol containing schemes (T-G and T-CY-G) showed that patients in the T-G group met the criteria to start leukapheresis earlier (median day 8, range 7-10) than those patients receiving T-CY-G (median day 13, range 11-17; P Ͻ 0.00001), with the number of peripheral CD34 + cells being similar between both groups on the day of commencement of collections. All T-G patients achieved 2.5 × 10 6 /kg CD34 + cells within the first leukapheresis procedure, while five out of seven patients (71.4%) receiv- Bone Marrow Transplantation ing T-CY-G attained that target dose (P Ͼ 0.05); a similar proportion of patients in T-G and in T-CY-G groups attained more than 5 × 10 6 CD34 + cells/kg in the first collection (80% vs 71.4%, respectively; P Ͼ 0.05) ( Table 2) .
Those patients heavily pre-treated (more than six cycles of chemotherapy) needed more leukapheresis procedures, but this population had a selection bias because some of them were included in a double transplantation protocol, so more procedures were performed in spite of attaining the threshold number of CD34 + cells within the first one. When comparing taxol priming schedules with mobilization with rhG-CSF alone, we found statistically significant differences in the proportion of patients who achieved the goal of 2.5 × 10 6 /kg CD34 + cells within the first procedure, in the number of aphereses performed, in the yield of CD34 + cells both on the first and in all collection procedures (Table 2) . Patients mobilized with rhG-CSF alone received the growth factor for a median of 4 days (range 4-7), an interval shorter than those receiving T-G (median 6 days, range 5 to 8, P Ͻ 0.0001), and individuals included in the T-CY-G group (median 11 days, range 9 to 14, P Ͻ 0.0001). Patients in the T-G group also underwent fewer days of rhG-CSF treatment than those included in T-CY-G protocol (P = 0.0003).
Toxicities
The mobilization therapy was generally well tolerated. One patient in each group of taxol containing schedules developed a pruriginous skin rash, which resolved after rhG-CSF treatment cessation. Mild to moderate muscle and bone pain was well controlled with acetaminophen. No patient required treatment discontinuation. No hypersensitivity reactions or peripheral neuropathy in association with taxol, nor CY-related hemorrhagic cystitis were observed.
Grade III and IV hematological toxicities differed between both taxol containing schedules. The median duration of severe and moderate neutropenia (ANC Ͻ0.5 × 10 9 /l, and Ͻ1 × 10 9 /l, respectively) was 0 days (range 0-1, and 0-2, respectively) for T-G patients, and 6 days (range 3-10, and 3-11, respectively) in those receiving T-CY-G, P = 0.0002. Moderate thrombocytopenia (Ͻ100 × 10 9 /l) extended for a median of 0 days (range 0-5), and 8 days (range 4-16), in the T-G and T-CY-G groups, respectively, P = 0.0004. Thrombocytopenia below 50 × 10 9 /l was also less frequent in patients mobilized with T-G than in those treated with T-CY-G (median 0 days, range 0-2, vs 7 days, range 3-7, respectively, P = 0.0002). Three patients in the T-CY-G group suffered febrile neutropenia requiring hospital admission, while no individual within the T-G group developed fever during mobilization (P = 0.007). Only two patients were transfused (both in the T-CY-G group) due to low hematological counts after leukapheresis: one patient was administered platelets, and the other packed red blood cells.
In the group of 22 patients receiving taxol, the days of neutropenia (ANC Ͻ1 × 10 9 /l), or thrombocytopenia (platelets Ͻ100 × 10 9 /l), correlated with a delay in the execution of the first apheresis (r = 0.88, r = 0.94, respectively), but did not influence the yield of the first apheresis procedure, nor the number of leukaphereses performed. On the day of initiation of leukapheresis, hematological parameters differed significantly in patients receiving T-G or T-CY-G schedules, with higher hematocrit values (31.8% vs 29.5%) (P = 0.02) and platelet numbers (139.6 vs 77.43 × 10 9 /l) (P = 0.0082), in the T-G group.
Discussion
Taxol has been successfully introduced into mobilization schedules for autologous transplantation in breast cancer patients. The drug causes no cumulative hematopoietic toxicity and while being effective in mobilizing PBPC it does not damage the stem cell pool. It has been previously hypothesized that taxol may synchronize cells better than other chemotherapeutic agents, 3 but the specific properties of the drug in facilitating mobilization of PBPC to date remains unknown. Most schedules use taxol in combination with other chemotherapeutic agents, mainly CY, and the hematopoietic growth factor, rhG-CSF. [3] [4] [5] [6] [7] [8] Limited information is available about the use of taxol as a single agent for the mobilization of PBSC. Previous reports show a similar 11, 12 or even a better mobilizing capacity of CD34 + cells by taxol than CY, 13 which would therefore be expected to result in subsequent better engraftment kinetics and faster complete hematological recovery. [14] [15] [16] A prospective study was undertaken in breast cancer patients to evaluate the effect of taxol with CY, or as a single chemotherapeutic agent, on CD34 + cell yield. Taxol containing schedules, in the presence or absence of CY, were shown to result in higher collections of CD34 + cells than rhG-CSF. Despite the controversy over the number of CD34 + cells required to support myeloablative regimens, a number greater than 2.5 × 10 6 /kg is considered to be sufficient for a safe hematopoietic reconstitution. 1, 17 Our data show that taxol in combination with rhG-CSF results in the collection of 2.5 × 10 6 /kg CD34 + cell target levels by a single apheresis procedure, and that in 80% of patients, that first collection procedure achieves more than 5 × 10 6 /kg CD34 + cells. With the administration of T-CY-G, 70% of patients attained the threshold 2.5 × 10 6 /kg CD34 + cell yield on the first collection day. The timing of the start of the mobilization was very reproducible in the T-G group, allowing the scheduling of the apheresis procedures by day 8. The duration of mobilization in order to reach target concentrations of peripheral blood CD34
+ cells was slightly more variable and significantly longer in our series of patients mobilized with the addition of CY to the priming schedule. The reduction in the total dose of rhG-CSF, and the decrease in expense for additional chemotherapy in the T-G group, indicate that the cost of the mobilization and collection procedures can be lessened with the use of T-G compared to T-CY-G priming schedule. These results, however, should be interpreted with caution due to the small number of patients included in the study. Nevertheless, it seems obvious that taxol alone with rhG-CSF can successfully mobilize CD34
+ cells, and that the addition of CY, while lengthening the mobilization procedure, does not seem to be significantly more effective in reaching the threshold number of 2.5-5.0 × 10 6 /kg CD34 + cells. Different taxol doses and schedules of administration have been reported either when using it as a single agent, or in combination with other chemotherapeutic agents.
3,5-8,11-13 Recently Burtness et al 11 in a phase I trial of taxol with rhG-CSF for PBSC mobilization, reported a number of adverse effects, mainly neutropenia and neuropathy. These side-effects were associated with the use of taxol at a dose equal or greater than 250 mg/m 2 as a 24 h infusion. In our series, taxol at 170 mg/m 2 /day was well tolerated, and no extrahematologic toxicities related to the use of the taxane were observed. The use of T-G was associated with only mild thrombocytopenia and neutropenia. The addition of CY to the mobilizing schedule aggravated the injurious effect of chemotherapy on bone marrow, resulting in 29% of patients requiring transfusion support, and 43% being hospitalized due to the development of febrile neutropenic episodes.
In conclusion, our data show that mobilization of CD34 + cells using taxol as a single chemotherapeutic agent at a dose of 170 mg/m 2 administered as a 24 h infusion, in association with rhG-CSF, is highly efficient, non-toxic and predictable. Priming of PBPC using the combination of CY and taxol is also effective in terms of CD34 + cell yield, but this schedule is associated with remarkable hematological toxicities. The ability of taxol to promote CD34 + cell mobilization makes it a useful agent to be considered in PBSC priming in patients with breast cancer.
